that Thank you, your you drop to have the call, you sharing It you at so experience fantastic like appreciate is would Houston. Drew. to can and in perspectives. We get Ziopharm. you here to We the team back from
TCR-T and the made In have this underscores Ziopharm in summary, advancements expects evolving the we play space. to prominent additions to role program our
clinical right at pursue right Drew here on hotspots system and with We are Ziopharm and in future. and the targets genetically two shots and the outside Combined, to right creates neoantigens Dr. two compelling patient-derived colleagues the tool, T-cells. targeting to paths the modify this Ziopharm at for goal the with NCI inside Sleeping or working Beauty with team Rosenberg we the are
other two programs. upon touch I will our now
the program. Let me CAR-T to turn
Rapid the venture, Manufacturer Greater Our China. to center we specific and as Personalized joint second which with our in on Beauty in for is or BioCell we MD built United through also as advancing collaboration program refer of States platform CD-XX the Eden RPM cancer CAR-T Anderson Sleeping are the
reiterate a rapid generate associated CAR-T Anderson. CAR-T technology plan MD for gene of Personalized transfer. with bound two Phase Sleeping IL-XX manufacturer later with colleagues within with is to We our of commence Manufacturer personalized CD-XX third-generation trial Rapid membrane at year Beauty days this to X The specific designed
for partner, ourselves. from With independence two set former challenges our we
process from was needs for and was unrecognized perhaps second the to clinical to the competitive manufacturing viewpoint. CAR-T and evaluate improve first the a The space
past ten three Let the from with months. me now learnings share these you
CAR-T target Ziopharm Recall CD-XX. other targets. that The which October unnamed milestones first is and on past other exclusive focused renegotiated one course that we last CD-XX for is relationships of only rights remained CAR the its approved among gaining
in potential. of me Our and needed excuse been in and the achieving cost We CAR-T work and TCR two to expense the CAR justify the work crowded in given targets – to space. develop cannot investors manufacturing clinic with new hurdles targets, and the the – time required patients have rob complexity CAR-T validate crowded competing validated untested of their the while
approach greatly However, complexity needed our TCRs based to our Ziopharm the reduce targeting superior have Furthermore, CAR strategic tumors. findings solid what commercial is the T-cell CARs that cost appeals. the an and is to plan for top-line is seeks and two provide existing that will what to targets of for be on
represents this untapped largely As is it another significant opportunity territory, for us.
work, by past the to achieve This required with ten XX% months understood we in of clinical during Secondly, T-cells forward confidence us moving viability threshold as have the great produce trials. gives the of how to FDA.
Thirdly, have for efforts. on we special lymphoblastic an transplantation. CAR-T that or CD-XX specific care identified is acute believe for base bone is Ziopharm’s the allogenic, established knowledge leukemia patients that only We marrow the opportunity with time-honored ALL to this we
who received commercially transplant therapies are patients go approved as from currently This concerned about justifiably many a relapse. treating CD-XX specific CAR-T to why is physicians receive on
CAR-T in one just CAR-T bone up transplantation. an procedures. by manufactured infusing further very we patients in they case for which seize who two relapse go represents as marrow want to transplantation. rapidly This now and but mentality for expensive patients the bone these cost allogenic This after not Ziopharm wish drives marrow our opening to
and ALL, this patients approved no some will there a therapies clinical as fill Ziopharm is into situation still death a number step a transplantation relapse. with as is for a While for now This sizable void. established cure are
appear have to we who forward. unnoticed patients prioritized as these Thus, go a path
lymphomas recipients leukemias new transplantation. and drug FDA with relapse investigational this year CD-XX application to who We to an treat expect with after file expressing later
of of will help of will that concept Personalized allogenic T-cells whether year assess a donor-derived design of product trial healthy or this were proved Manufacturing a the of lymphoid impact can commercially available consisting undermining Ziopharm currently relapse depletion CAR-T. deliver progress leukemia, which also negative favorably The Rapid Thus, for who rates CAR-T. particularly patients is needed the the with effectiveness and CD-XX whether we is
prioritized continue we personalized our program CD-XX will malignancies. we to based autologous us regard patients address regarding CD-XX With with Therapeutics our from continuum specific effort, CD-XX on to this to While venture to Asia returned CAR-T advance the productive BioCell, allow the joint our Triumph following manufacturer. to rapid expressing entire meetings have we Eden of with our partner develop
In facilities and Greater Shanghai, the in to facilities. partner and GMP officials hospitals why leadership China development. state-of-the-art with excellent for joint clinical trip at high-quality and plans positions our met and we their the toured ideal our as Triumph trials reinforced This venture have with relationships this team conduct they to for a bodies, leading are frontline commitment advance regulatory
activates immune precisely our can on program. IL-XX to production of interleukinXX T-cells solid recruit the regulate into Ziopharm words tumors. which the few a system human Controlled Finally, cancer-fighting
based powerful advancing survival, with an on likely is sustain in switch our recruit within recurrent checkpoint demonstrated the a a monotherapy tumor. IL-XX studies, apparent immune which and we T-Cell IL-XX treatment the is for to developing as response of This the for IL-XX’s in ability overall combination clinical and in drug basis glioblastoma. as inhibitors, improvement controlled technology have By
our combine to rationale immune IL-XX compelling with the checkpoint provide which PDX inhibitors. controlled upregulate T-cells These
clinical our emphasize Let regarding me recent a news. of quickly points couple
trial up cohort with combination patients completed the the to quarter. OPDIVO, during expect enrollment We we Phase study our level. received our a enroll Based in expand Firstly, dosing this to study. third additional the investigators on profile, X requested highest favorable safety second and at in approval XX now to dosing
we and Libtayo same begun With Regeneron’s patient we interest have about enrolling patients enroll. seen have approximately and in anticipate combination XX ten X with OPDIVO strong briskly clinician to the this Next, in we level Phase our will the this study, study that trial sites enrollment in June.
in interim a morning, this provide opinion just we update received announced program drug and delighted June, designation Annual trials we last And positive are Society the monotherapy lastly, another data November. AACR per orphan as therapy for Orleans, in of expect this Europe. as Meeting at to Neuro-Oncology combination the the for that Next, New
most In one at not past has of the been the periods Ziopharm. productive my closing, if quarter tenure during
and that efforts the the reshape, in on of and have momentum quarter work transformational year fourth to restructure we ever build since. to Our last with refocus beginning company
ten past as a emerged company. tangibly these Ziopharm Over has different months,
We are executing our on timelines.
We have secured our continue new welcome and the balance attract throughout and we talent to organization. sheet
and high We and deliver vision, expectations have of needs on shareholders, the the resources the the partnerships to we our our of continue data, to patients the for standards set ourselves.
And with for the call operator turn that, questions. the over we to
